Malarone is a prescription-only antimalarial medicine used for both the prevention and treatment of malaria caused by Plasmodium falciparum. It is especially useful in regions where resistance to other antimalarial drugs is common. Malarone is suitable for adults and children over 11 kg and is typically recommended for short-term travel to malaria-endemic areas. Its convenient once-daily dosing and high efficacy make it a trusted choice for travellers and healthcare providers.
How It Works
Malarone contains a combination of atovaquone and proguanil hydrochloride, two antimalarial agents that act synergistically. Atovaquone interferes with the parasite’s ability to reproduce by disrupting mitochondrial electron transport, while proguanil inhibits the parasite’s ability to replicate DNA through dihydrofolate reductase inhibition. This dual mechanism effectively eliminates the malaria parasite at both liver and blood stages, preventing infection or clearing it from the bloodstream.
Why Choose Malarone
Malarone is highly effective and well-tolerated, with a shorter post-travel dosing period compared to older antimalarials like doxycycline or mefloquine. It has a low incidence of serious side effects and is less likely to cause photosensitivity or vivid dreams, making it a more convenient and comfortable option for many travellers. Its once-daily tablet format improves adherence, and its rapid onset offers protection within just 1–2 days of starting treatment.
Important Note
Malarone must be taken exactly as directed to ensure full protection or successful treatment. Missing doses or stopping early can lead to treatment failure or resistance. It is not suitable for people with severe renal impairment and must be used with caution in pregnant or breastfeeding women. Malarone does not offer complete protection—mosquito bite avoidance (e.g. nets, repellents) is still essential. Always consult a travel health specialist or GP before starting antimalarial treatment.
